Wells Fargo & Company MN grew its position in Flexion Therapeutics, Inc. (NASDAQ:FLXN) by 37.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 171,351 shares of the specialty pharmaceutical company’s stock after buying an additional 46,634 shares during the period. Wells Fargo & Company MN owned approximately 0.54% of Flexion Therapeutics worth $3,464,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in FLXN. Swiss National Bank grew its holdings in shares of Flexion Therapeutics by 13.2% in the 1st quarter. Swiss National Bank now owns 35,911 shares of the specialty pharmaceutical company’s stock valued at $966,000 after buying an additional 4,200 shares during the period. Ameriprise Financial Inc. bought a new stake in Flexion Therapeutics in the 1st quarter valued at $1,246,000. Parametric Portfolio Associates LLC lifted its position in Flexion Therapeutics by 79.0% in the 1st quarter. Parametric Portfolio Associates LLC now owns 27,600 shares of the specialty pharmaceutical company’s stock valued at $743,000 after acquiring an additional 12,181 shares in the last quarter. American International Group Inc. lifted its position in Flexion Therapeutics by 52.3% in the 1st quarter. American International Group Inc. now owns 16,212 shares of the specialty pharmaceutical company’s stock valued at $436,000 after acquiring an additional 5,569 shares in the last quarter. Finally, Asset Management One Co. Ltd. bought a new stake in Flexion Therapeutics in the 1st quarter valued at $319,000. 83.26% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://theolympiareport.com/2017/10/18/flexion-therapeutics-inc-flxn-shares-bought-by-wells-fargo-company-mn.html.

In related news, insider Yamo Deniz acquired 1,375 shares of the stock in a transaction on Thursday, August 31st. The shares were acquired at an average price of $25.40 per share, with a total value of $34,925.00. Following the completion of the transaction, the insider now owns 5,000 shares in the company, valued at approximately $127,000. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders acquired 5,375 shares of company stock worth $131,575. Insiders own 15.98% of the company’s stock.

Several research firms recently commented on FLXN. Zacks Investment Research cut shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. Laidlaw reaffirmed a “buy” rating and issued a $38.00 price objective (up from $35.00) on shares of Flexion Therapeutics in a research report on Tuesday, October 10th. Janney Montgomery Scott boosted their price objective on shares of Flexion Therapeutics to $570.00 and gave the company a “fair value” rating in a research report on Tuesday, October 10th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $37.00 price objective (up from $35.00) on shares of Flexion Therapeutics in a research report on Monday, October 9th. Finally, Needham & Company LLC boosted their price objective on shares of Flexion Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, October 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $88.50.

Shares of Flexion Therapeutics, Inc. (NASDAQ FLXN) opened at 25.37 on Wednesday. The company’s market capitalization is $809.43 million. The stock has a 50 day moving average of $25.16 and a 200-day moving average of $22.58. Flexion Therapeutics, Inc. has a one year low of $15.93 and a one year high of $32.25.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). On average, equities analysts forecast that Flexion Therapeutics, Inc. will post ($3.80) earnings per share for the current fiscal year.

Flexion Therapeutics Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.